Renalytix plc (RNLX)

NASDAQ: RNLX · IEX Real-Time Price · USD
2.60
-0.03 (-1.14%)
At close: Aug 8, 2022 4:00 PM
2.64
+0.04 (1.54%)
After-hours: Aug 8, 2022 4:01 PM EDT
-1.14%
Market Cap 97.19M
Revenue (ttm) 2.61M
Net Income (ttm) -49.94M
Shares Out 37.38M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 163,432
Open 2.68
Previous Close 2.63
Day's Range 2.55 - 2.74
52-Week Range 2.23 - 31.00
Beta 1.69
Analysts Buy
Price Target 23.04 (+786.2%)
Earnings Date Jun 30, 2022

About RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical tri... [Read more...]

Industry Health Care Technology
IPO Date Jul 17, 2020
Employees 51
Stock Exchange NASDAQ
Ticker Symbol RNLX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for RNLX stock is "Buy." The 12-month stock price forecast is 23.04, which is an increase of 786.15% from the latest price.

Price Target
$23.04
(786.15% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX™...

98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022

LONDON and SALT LAKE CITY, June 30, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical man...

Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30

NEW YORK and SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022 financial results on Thursda...

1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 t...

Late-breaking data presented at American Diabetes Association Scientific Sessions® demonstrates increased adherence to care guidelines for physicians using KidneyIntelX risk assessment to improve outcom...

3 Penny Stocks That Wall Street Thinks Are Undervalued

By and large penny stocks deservedly have a bad rap, but right now selective attention to what Wall Street has to say makes sense for buyers. The post 3 Penny Stocks That Wall Street Thinks Are Underval...

Other symbols: AGFYCURI

KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International D...

Data shared in oral presentation at American Diabetes Association 82 nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cau...

Renalytix Announces Two Data Presentations on KidneyIntelX™ at American Diabetes Association 82nd Scientific Sessions®

Real-world clinical utility in 1,112 patients tested with KidneyIntelX

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renalytix Plc - RNLX

NEW YORK , April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Renalytix Plc ("Renalytix" or the "Company") (NASDAQ: RNLX).  Such investors are advised to cont...

Renalytix plc successful completion of $30.0 million financing package

Director/PDMR Dealing Director/PDMR Dealing

Renalytix plc Issue of shares

NEW YORK and SALT LAKE CITY, April 08, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 22,814 new ordinary...

Renalytix announces a $30.0 million financing package

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR IN OR INTO ...

Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022

LONDON and SALT LAKE CITY, March 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical ma...

Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors

NEW YORK and SALT LAKE CITY, March 30, 2022 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced that, following the Company's announcement on February 22, 2022, Timothy Scannell...

Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Di...

KidneyIntelX RAPID biobank program and partners on track to reach over 30,000 biospecimens with matched electronic health records from multiple centers across the U.S. KidneyIntelX RAPID biobank program...

Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31

NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 finan...

Renalytix Launches National Physician Access To KidneyIntelX Platform

Renalytix plc (NASDAQ: RNLX) has launched its new provider access portal, myIntelX, to provide nationwide online access for physicians to order KidneyIntelX bioprognostic testing. KidneyIntelX enables e...

Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform

myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners myIntelX will be launching in ...

Renalytix to Present at Cowen 42nd Annual Health Care Conference

NEW YORK and SALT LAKE CITY, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virt...

Renalytix to Present at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

NEW YORK and SALT LAKE CITY, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming BTIG...

Renalytix AI PLC Sponsored ADR (RNLX) Surges 10.4%: Is This an Indication of Further Gains?

Renalytix AI PLC Sponsored ADR (RNLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

Positive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug Therapy

American Journal of Nephrology data demonstrates KidneyIntelX successfully monitors patient response to SGLT2 therapy in 1,325 CANagliflozin CardioVAScular Assessment Study (CANVAS) multinational clinic...

Renalytix Appoints Jean M. Casner as Chief Human Resources Officer

NEW YORK and SALT LAKE CITY, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that Jean M. Casner joined the Company this week on January 3, 2022 as Senior Vice...

Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare Conference

NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40th...

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022

NEW YORK and SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical m...

Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7

NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesd...